TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 12,050 shares, a growth of 52.4% from the July 15th total of 7,908 shares. Based on an average daily trading volume, of 3,956 shares, the short-interest ratio is presently 3.0 days.
TriSalus Life Sciences Trading Up 78.6%
Shares of TLSIW opened at $1.00 on Wednesday. TriSalus Life Sciences has a 52 week low of $0.44 and a 52 week high of $2.29. The firm’s 50-day simple moving average is $0.83 and its 200 day simple moving average is $1.00.
Hedge Funds Weigh In On TriSalus Life Sciences
Several institutional investors and hedge funds have recently made changes to their positions in the company. Cerity Partners LLC acquired a new position in TriSalus Life Sciences in the 4th quarter valued at $1,374,000. Citadel Advisors LLC increased its position in TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after buying an additional 103,336 shares during the period. Aristeia Capital L.L.C. acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter worth $43,000. Finally, Fort Baker Capital Management LP bought a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at about $44,000.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.
Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Tesla’s Cybercab Launch Could Reshape Margins for Uber and Lyft
- Pony AI Stock Gains Traction as Robotaxi Fleet Expands Globally
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
